AAS vs Warfarin in Low Risk TAVR

We are still discussing the adequate antithrombotic scheme after transcatheter aortic valve replacement (TAVR). Additionally, we are treating a much wider array of patients ranging from low risk to inoperable. 

AAS vs Warfarina en TAVI de bajo riesgo

And there is yet one more important point: hypo-attenuated leaflet thickening diagnosed by CT. We are still unaware of the impact they have on device durability at long term, which is overly concerning in low-risk patients.  

This study recently published in Circ Cardiovasc Interv has tried to answer some of the questions above. The study openly randomized 1:1 low risk patients undergoing transfemoral TAVR to low-dose aspirin or warfarin plus low-dose aspirin for 30 days. 

It used CT or transesophageal echocardiography after one month to assess the presence of hypo-attenuated leaflet thickening, reduced leaflet motion, mean gradient ≥20 mm Hg, effective orifice area ≤1.0 cm2, moderate or severe regurgitation, stroke, or transient ischemic attack.


Read also: Medical Therapy Optimization Achieved Prior Clinical Trial.


50 patients received aspirin and 44 warfarin plus aspirin, and 30 who could not be randomized were enrolled into a registry.

The primary end point occurred in 26.5% of patients receiving aspirin vs. 7% of patient receiving aspirin and warfarin (p=0.014; OR 4.8). The difference was based on hypo-attenuated leaflet thickening rate (16.3% vs 4.8%; p=0.07).

There was no excess bleeding with warfarin during the first 30 days. 

Conclusion

In low-risk patients undergoing TAVR, anticoagulation with warfarin could prevent leaflet dysfunction at short term with no excess bleeding. 

Original Title: Randomized Trial of Aspirin Versus Warfarin After Transcatheter Aortic Valve Replacement in Low-Risk Patients.

Reference: Toby Rogers et al. Circ Cardiovasc Interv. 2021 Jan;14(1):e009983. doi: 10.1161/CIRCINTERVENTIONS.120.009983.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

 

More articles by this author

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Coronary Artery Disease in Aortic Stenosis: CABG + SAVR vs. TAVR + PCI: Data from Spanish Centers

Multiple randomized studies have shown comparable or superior efficacy of transcatheter aortic valve replacement (TAVR) vs. coronary artery bypass graft (CABG).  However, many of...

TCT 2024 | TRISCEND II: A New Hope in Percutaneous Tricuspid Valve Replacement

Advanced tricuspid regurgitation (TR) is a debilitating disease associated with heart failure and increased mortality.  Edge-to-edge repair has been shown to improve both clinical condition...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....